These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 28556890)

  • 1. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
    Moreau P; de Wit E
    Br J Haematol; 2017 Oct; 179(2):198-218. PubMed ID: 28556890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
    Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
    Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
    Xu W; Sun X; Wang B; Guo H
    Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.
    Ailawadhi S; Cheng M; Cherepanov D; DerSarkissian M; Stull DM; Hilts A; Chun J; Duh MS; Sanchez L
    Curr Probl Cancer; 2024 Jun; 50():101078. PubMed ID: 38547609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
    Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
    Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy sequencing strategies in multiple myeloma: who, what and why?
    Costello C; Mikhael JR
    Future Oncol; 2018 Jan; 14(2):95-99. PubMed ID: 29219615
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of novel therapies in high-molecular-risk multiple myeloma.
    Lancman G; Tremblay D; Barley K; Barlogie B; Cho HJ; Jagannath S; Madduri D; Moshier E; Parekh S; Chari A
    Clin Adv Hematol Oncol; 2017 Nov; 15(11):870-879. PubMed ID: 29200420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
    Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
    J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma.
    Touzeau C; Antier C; Moreau P
    Future Oncol; 2021 Mar; 17(9):993-998. PubMed ID: 33289427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutics in multiple myeloma.
    Stewart AK
    Hematology; 2012 Apr; 17 Suppl 1(0 1):S105-8. PubMed ID: 22507794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixazomib in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
    Nijhof IS; van de Donk NWCJ; Zweegman S; Lokhorst HM
    Drugs; 2018 Jan; 78(1):19-37. PubMed ID: 29188449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
    Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
    Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
    Ashjian E; Redic K
    J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitors for the treatment of multiple myeloma.
    Scalzulli E; Grammatico S; Vozella F; Petrucci MT
    Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular targeting agents for multiple myeloma].
    Fujii S; Abe M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.